KYMR logo

KYMERA THERAPEUTICS INC

KYMRNASDAQ
πŸ† #806 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track KYMR
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$9.84B
Small Cap
πŸ“ˆRevenue Growth (YoY)
134.8%
High Growth
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
93.8x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for KYMR.

Trading Snapshot

Day Range
β€”
52-Week Range
$63.69 – $142.92
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
85.4M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$39M
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
93.8x
EPS (TTM)
$-3.24
Dividend Yield
β€”
Dilution (1yr)
+5.5%
KYMR logo

KYMERA THERAPEUTICS INC

KYMR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$39Mβ–Ό βˆ’16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$349Mβ–² +33.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$234Mβ–² +13.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.4Mβ–² +5.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$275Mβ–² +$242M YoY
StockOtter Β· stockotter.space

About KYMERA THERAPEUTICS INC

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.